EY vs Zühlke: full comparison for 2026
Quick verdict
EY (4.2/5) edges ahead of Zühlke (4.0/5) overall. EY is the better choice for enterprises building AI risk into existing controls. Zühlke is the stronger option for swiss and European health and finance firms. The right choice depends on how independent you need the advice to be, your regulatory exposure, and your budget.
EY vs Zühlke: head-to-head summary
| Criterion | EY | Zühlke |
|---|---|---|
| Founded | 1989 | 1968 |
| HQ | London, UK | Schlieren, Switzerland |
| Team size | ~400,000 | ~1,600 |
| Rating | 4.2 / 5 | 4.0 / 5 |
| Primary differentiator | AI risk work folded into existing technology risk and controls programs | Partner-owned advisory and engineering for regulated health and finance work |
| Pricing model | Engagement fees per scope; rates not published | Consulting and project fees; rates not published |
| Min. engagement | Not disclosed | Not disclosed |
| Primary tech stack | EU AI Act, NIST AI RMF, GDPR | EU AI Act, GDPR, Azure |
| Industries served | Financial services, Insurance, Public sector, Energy, Consumer | Healthcare, Medical devices, Banking, Insurance, Manufacturing |
EY vs Zühlke: overview
EY
EY was formed by the 1989 merger of Ernst & Whinney and Arthur Young and employs about 400,000 people. Its advisory teams cover responsible AI, AI risk, and compliance programs, and its technology risk leaders have spoken publicly about how far real AI assurance still has to go. That candor is useful for buyers who want an honest view of what can be certified today. Like the rest of the Big Four, it sells implementation as well.
Zühlke
Zühlke was founded in Switzerland in 1968, is headquartered in Schlieren near Zurich, and is owned by its partners. Directory figures put it at about 1,600 people across Europe and Asia. Its data and AI consultants work on strategy, governance, and responsible AI, mostly for health and financial clients, and the same firm builds the resulting systems. Partner ownership means no private equity or parent company is pushing a sales agenda.
Services and capabilities: EY vs Zühlke
| Capability | EY | Zühlke |
|---|---|---|
| Readiness assessment | ✓ | ✓ |
| Use-case prioritization | ✗ | ✗ |
| TCO / ROI modeling | ✗ | ✗ |
| AI governance & EU AI Act | ✓ | ✓ |
| Build vs. buy advice | ✗ | ✗ |
| Independent audit or assurance | ✓ | ✗ |
| Roadmap any vendor can implement | ✗ | ✗ |
| Delivery capability after advice | ✓ | ✓ |
Frameworks and platforms: EY vs Zühlke
| Framework / platform | EY | Zühlke |
|---|---|---|
| EU AI Act | ✓ | ✓ |
| GDPR | ✓ | ✓ |
| DORA | N/A | N/A |
| NIST AI RMF | ✓ | N/A |
| ISO/IEC 42001 | N/A | N/A |
| Azure | ✓ | ✓ |
| AWS | N/A | ✓ |
| Google Cloud | N/A | N/A |
Pricing comparison: EY vs Zühlke
| Criterion | EY | Zühlke |
|---|---|---|
| Minimum engagement | Not disclosed | Not disclosed |
| Engagement models | Fixed-scope assessment, Multi-use-case advisory, Audit or certification, Delivery team | Fixed-scope assessment, Multi-use-case advisory, Delivery team |
| Rate transparency | Not public | Not public |
| Price tier | Mid-market | Mid-market |
Target audience comparison: EY vs Zühlke
| Dimension | EY | Zühlke |
|---|---|---|
| Best company size | Enterprise | Mid-market to enterprise |
| Best industries | Financial services, Insurance, Public sector | Healthcare, Medical devices, Banking |
| Best use cases | Adding AI risk to an existing controls framework., Responsible AI policies for a large insurer. | Responsible AI planning for a medical-device maker., AI governance at a Swiss bank or insurer. |
| Typical project type | Fixed-scope assessment | Fixed-scope assessment |
EY vs Zühlke: pros and cons
| EY | |
|---|---|
| + | Ties AI risk to controls frameworks finance teams already use |
| + | Realistic public view on the limits of AI assurance |
| + | Large global bench |
| - | Premium fees |
| - | Sells delivery alongside advice |
| - | Audit-client independence rules apply |
| Zühlke | |
|---|---|
| + | Partner-owned, with no investor or parent shaping priorities |
| + | Long experience with medical-device and financial regulation |
| + | Advice and engineering in one firm |
| - | Swiss rates are high |
| - | Advice usually leads into its own delivery |
| - | Headcount figures come from directories |
Who should choose EY?
A typical fit: adding AI risk to an existing controls framework.
AI risk work folded into existing technology risk and controls programs. Minimum engagement is not publicly disclosed. Works best with clients in Financial services, Insurance, Public sector, Energy, Consumer.
Who should choose Zühlke?
A typical fit: responsible AI planning for a medical-device maker.
Partner-owned advisory and engineering for regulated health and finance work. Minimum engagement is not publicly disclosed. Works best with clients in Healthcare, Medical devices, Banking, Insurance, Manufacturing.
Decision matrix: EY vs Zühlke
| Your situation | Recommended choice |
|---|---|
| You want advice with no build contract attached | Neither; write the build as a separate decision |
| Finance needs run costs before approving anything | Neither lists cost modeling; ask for a sample |
| Some of your use cases may be high-risk under the EU AI Act | Both cover AI Act classification |
| You need an outside check on a system already built | EY |
| You want the same firm to build what it recommends | Both can deliver |
| Your budget is at the lower end | Compare: EY (Not disclosed) vs Zühlke (Not disclosed) |
| You need advisers in many countries at once | EY |
Use case fit: EY vs Zühlke
| Use case | EY fit | Zühlke fit | Winner |
|---|---|---|---|
| Adding AI risk to an existing controls framework. | Strong | Limited | EY |
| Responsible AI policies for a large insurer. | Strong | Limited | EY |
| Responsible AI planning for a medical-device maker. | Limited | Strong | Zühlke |
| AI governance at a Swiss bank or insurer. | Limited | Strong | Zühlke |
Verdict: EY vs Zühlke
EY (4.2/5) is the stronger overall choice for most AI Advisory projects. AI risk work folded into existing technology risk and controls programs.
Zühlke (4.0/5) is worth a look if you need AI governance at a Swiss bank or insurer. If your situation matches that, Zühlke is a competitive option.
Related comparisons
EY vs Zühlke FAQ
Is EY better than Zühlke?
EY (4.2/5) scores higher overall, but "better" depends on your use case. EY's strongest advantage: ties AI risk to controls frameworks finance teams already use. Zühlke's strongest advantage: partner-owned, with no investor or parent shaping priorities.
How do EY and Zühlke differ in pricing?
EY's pricing: engagement fees per scope; rates not published. Zühlke's pricing: consulting and project fees; rates not published. Any hourly bands shown come from Clutch, not a published rate card, so a scoping call is still needed for a project quote.
Which is better for enterprise: EY or Zühlke?
EY is the larger team and typically the better enterprise-scale choice. For very large programmes, verify team size and compliance coverage directly with each firm before shortlisting.
What are the main differences between EY and Zühlke?
EY's primary differentiator is: AI risk work folded into existing technology risk and controls programs. Zühlke's primary differentiator is: partner-owned advisory and engineering for regulated health and finance work. They also differ in team size (~400,000 vs ~1,600), minimum engagement (Not disclosed vs Not disclosed), and primary industries served (Financial services, Insurance vs Healthcare, Medical devices).
Verify all details directly with each firm before making a decision.